Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...
The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...
Real world outcomes of darolutamide efficacy and safety in treating non-metastatic and metastatic hormone-sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). Comparative effectiveness of ...
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results